Completed PHASE3 INTERVENTIONAL 2-arm NCT02781727

A Phase 3 Trial of the Safety, Tolerability and Efficacy of TransCon hGH Weekly Versus Daily hGH in Children With Growth Hormone Deficiency (GHD)

A Multicenter, Phase 3, Randomized, Open-label, Active-controlled, Parallel-group Trial Investigating the Safety, Tolerability, and Efficacy of TransCon hGH Administered Once a Week Versus Standard Daily hGH Replacement Therapy Over 52 Weeks in Prepubertal Children With Growth Hormone Deficiency (GHD)

Sponsor: Ascendis Pharma Endocrinology Division A/S

Conditions Endocrine System Diseases Growth Hormone Deficiency, Pediatric Hormones Pituitary Diseases hGH (Human Growth Hormone)

Interventions Once daily subcutaneous injection of Genotropin Once weekly subcutaneous injection of TransCon hGH

Updated 13 times since 2017 Last updated: Dec 6, 2021 Started: Dec 13, 2016 Primary completion: Jan 17, 2019 Completion: Jan 17, 2019

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Endocrine System Diseases and Growth Hormone Deficiency, Pediatric, this trial is completed. The trial is conducted by Ascendis Pharma Endocrinology Division A/S and has accumulated 13 data snapshots since 2016. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

13 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2022 — Jul 2024 [monthly]

Completed PHASE3
Oct 2021 — Jan 2022 [monthly]

Completed PHASE3

▶ Show 8 earlier versions

Jan 2021 — Oct 2021 [monthly]

Completed PHASE3
Jan 2020 — Jan 2021 [monthly]

Completed PHASE3
May 2019 — Jan 2020 [monthly]

Completed PHASE3

Status: Active Not Recruiting → Completed
Mar 2019 — May 2019 [monthly]

Active Not Recruiting PHASE3
Jun 2018 — Mar 2019 [monthly]

Active Not Recruiting PHASE3
Jan 2018 — Jun 2018 [monthly]

Active Not Recruiting PHASE3

Status: Recruiting → Active Not Recruiting
Feb 2017 — Jan 2018 [monthly]

Recruiting PHASE3
Jan 2017 — Feb 2017 [monthly]

Recruiting PHASE3

First recorded

Dec 2016

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Ascendis Pharma Endocrinology Division A/S

Data source: Ascendis Pharma A/S

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Athens, Greece , Birmingham, United States , Centennial, United States , Clayton, Australia , Dallas, United States , Fort Worth, United States , Gdansk, Poland , Grafton, New Zealand , Iași, Romania , Izhevsk, Russia and 38 more locations